Spatial Concept – Page 15

Sanofi Restructures US Commercial Vaccine Group Amid Cost-Saving Campaign

2 years ago talkbio0Tagged Commercial Vaccine, Cost-Savings Campaign, Effectiveness, Efficiency, Employee, Evolving, Market, Optimization, Outplacement, restructuring, sanofi, streamlined strategic sales, Structure, Vaccines

Sanofi, Restructuring, US Commercial Vaccine Group, Cost-Savings Campaign, Streamlined Strategic Sales Structure, Evolving Vaccine Market, Optimization for Efficiency and Effectiveness, Employee Support and Outplacement Assistance

Biopharma Layoff Tracker 2024: Sanofi, Vedanta, Fujifilm, and More Companies Reduce Workforce

2 years ago talkbio0Tagged Acorda, Biological Factors, Biopharma layoffs, Cara, Eiger, Fujifilm, Genomic Orientation, Invitae, Pfizer, sanofi, Vedanta

Biopharma layoffs, Sanofi, Vedanta, Fujifilm, Acorda Therapeutics, Eiger BioPharmaceuticals, Invitae, Sientra, Strand Therapeutics, Cara Therapeutics, Pfizer

CMS to Increase Reimbursement for New Sickle Cell Gene Therapies through Outcomes-Based Agreements

2 years ago talkbio0Tagged Administrative action, Burden, Casgevy, Cells, Centers for Medicaid and Medicare (CMS) Pnl, Central, CGT, Equitable Access, Fertility, Grail, Increased, Lyfgenia, Medicaid Access, Medicare & Medicaid Services, OBAs, Outcomes-Based Agreements, Reimbursement, sickle cell gene therapies

CMS (Centers for Medicare & Medicaid Services), Sickle Cell Gene Therapies, Increased Reimbursement, Outcomes-Based Agreements (OBAs), Cell and Gene Therapy (CGT) Access Model, Medicaid Access, Casgevy, Lyfgenia, Fertility Preservation Services, Equitable Access, Administrative Burden Reduction

The Transformative Future of Specialist Distribution: Adaptive Strategies and Technological Innovations

2 years ago talkbio0Tagged **Last-Mile Solutions**:, Adaptive Strategies, Artificial Intelligence, Automation, Data Integration, Global Expansion, Hospital specialist, Smart Distribution Centers, Spatial Distribution, Technological Innovations, trends qualifier, Virtual Distribution

Specialist Distribution, Future Trends, Adaptive Strategies, Technological Innovations, Automation, Artificial Intelligence, Last-Mile Solutions, Virtual Distribution, Data Integration, Global Expansion, Smart Distribution Centers

Diagonal Therapeutics Secures $128 Million Series A Funding through Innovative Antibody Agonists

2 years ago talkbio0Tagged Antibody agonism, Cells, Diagonal, Funding, Rare Diseases, switches

Diagonal Therapeutics, Series A funding, Antibody agonism, Cellular “on” switches, Rare diseases

Diagonal Therapeutics Secures $128 Million Funding to Target Rare Diseases

2 years ago talkbio0Tagged Antibodies, Blue-chip, Chronic anemia, Diagonal, Merck's, Orphan disease treatment, Rare diseases focus, research, Winrevair

Diagonal Therapeutics, Antibody biotech, $128 million funding, Rare diseases focus, Orphan disease treatment, Chronic anemia, Merck’s Winrevair related research, Blue-chip investors

Bristol Myers Squibb’s KRAZATI Confirmed Effective in Pivotal Phase 3 KRYSTAL-12 Trial Following Accelerated Approval

2 years ago talkbio0Tagged Accelerated Approval, adagrasib, Approved, bristol-myers, Clinical Benefit, Confirmatory Trial, Continuous, June 21/ 2024, KRASG12C mutation, KRAZATI, KRYSTAL-12, Locally, Metastatic to, Non-Small Cell Lung Carcinoma, ORR, Overall response rate, PDUFA, Primary Endpoint, Progression-Free Survival, squibb, United States Food and Drug Administration, Verification of Theories

Bristol Myers Squibb, KRAZATI (adagrasib), Pivotal Phase 3 trial, KRYSTAL-12 study, Primary endpoint met, Progression-free survival (PFS), Overall response rate (ORR), Confirmatory trial, Non-small cell lung cancer (NSCLC), Locally advanced or metastatic, KRASG12C mutation, Accelerated approval, Continued approval contingent on clinical benefit verification, FDA assigned PDUFA goal date of June 21/ 2024

Gilead Partners with Xilio Therapeutics for Novel Tumor-Activated IL-12 Program

2 years ago talkbio0Tagged development aspects, interleukin-12, Xilio, XTX301

interleukin-12, Xilio, XTX301, development aspects

“#FierceMadness 2024: Best Biotech Name Tournament Round of 32 Results”

2 years ago talkbio0Tagged Beyfortus, biotech, Biotech Name, Daybue, drug names, Fierce, FierceMadness, Marketing Suitability, Mounjaro, results, Round shape, Tournament, Wainua

#FierceMadness, Best Biotech Name Tournament, Round of 32 Results, Drug Names, Marketing Suitability, Mounjaro, Daybue, Beyfortus, Wainua, Fierce Biotech, Voting Results

FDA Unexpectedly Postpones Approval Decision for Eli Lilly’s Donanemab, Schedules AdComm Review

2 years ago talkbio0Tagged Accelerated Approval, Aduhelm, Anticipated, Approved, aspects of adverse effects, Central Nervous System Agents, Cerebral Edema, Clinical Trials, Deferred, Donanemab, Effectiveness, eli lilly, Full approval, Hemorrhage, Leqembi, PCNS, Peripheral, precedent, Review [Publication Type], Safety, United States Food and Drug Administration

Donanemab, Eli Lilly, FDA delay, Approval postponement, Peripheral and Central Nervous System Drugs Advisory Committee (PCNS), Safety and efficacy review, Clinical trial results, Brain swelling and bleeding side effects, Accelerated approval declined, Leqembi and Aduhelm precedent, Full approval anticipated, Accelerated approval rejected.